2. Search Result
Search Result
Results for "

low toxicity

" in MedChemExpress (MCE) Product Catalog:

255

Inhibitors & Agonists

3

Screening Libraries

14

Fluorescent Dye

13

Biochemical Assay Reagents

4

Peptides

1

MCE Kits

14

Natural
Products

5

Isotope-Labeled Compounds

6

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1262
    BODIPY-TS

    Thiol-green 2

    		 Fluorescent Dye Others
    BODIPY-TS (Thiol-green 2) is a fast response and thiol-specific turn-on probe. BODIPY-TS utilizes the thiosulfonate scaffold as a thiol recognition unit. BODIPY-TS has low toxicity, and features high selectivity, low detection limit, and quantitative reaction to thiols . Ex: 490 nM; Em: 515 nM.
    BODIPY-TS
  • HY-160533
    IKZF1-degrader-2

    		IKZF Family Cancer
    IKZF1-degrader-2 (Compound 3) is an IKZF1 degrader. IKZF1-degrader-2 has anticancer activity and low toxicity .
    IKZF1-degrader-2
  • HY-163153
    Anticancer agent 184

    		Apoptosis Cancer
    Anticancer agent 184 (Compound 6o) is a novel, effective and low toxic anticancer drug. Anticancer agent 184 induces apoptosis by blocking the S phase .
    Anticancer agent 184
  • HY-155471
    IMP 245

    		Others Others
    IMP 245 is a symmetric di-HSG bivalent hapten. IMP 245 has low toxicity, high affinity binding to available antibodies and absence of cross reactivity or non-specific binding with body components .
    IMP 245
  • HY-N7262
    Hydroxyvalerenic acid

    		Others Cancer
    Hydroxyvalerenic acid is isolated from Verbena officinalis, has a low toxicity with IC50 values of 123 and 165 μM against GLC4 and COLO 320 cells, respectively .
    Hydroxyvalerenic acid
  • HY-156339
    GABA receptor Antagonist 1

    		GABA Receptor Others
    GABA receptor Antagonist 1 (compound 7w) inhibits Px RDL1 GABAR with an IC50 value of 7.08 nmol/L. GABA receptor Antagonist 1 shows insecticide activity against P. xylostella, S. frugiperda, S. exigua, and S. litura, with LC50 of 0.09, 0.84, 0.87, and 0.68 mg/L respectively. GABA receptor Antagonist 1 shows a medium toxicity to honeybee (48 h, ID50 = 2.22 μg/adult), and low toxicity to zebrafish (LC50: 42.4 mg/L) .
    GABA receptor Antagonist 1
  • HY-157850
    BP-M345

    		Others Cancer
    BP-M345 (compound 5) is a potent, cancer cell-targeting antiproliferative agent that exhibits low toxicity to non-tumor cells. BP-M345 inhibits cancer cell proliferation with a GI50 value ranging from 0.17 to 0.45 μM .
    BP-M345
  • HY-147693
    COX-1/2-IN-3

    		COX Inflammation/Immunology
    COX-1/2-IN-3 (Compound 7a) is a COX-1 and COX-2 inhibitor. COX-2-IN-15 shows anti-inflammatory activity with low toxicity .
    COX-1/2-IN-3
  • HY-146286
    Anticancer agent 44

    		Apoptosis Cancer
    Anticancer agent 44 (compound 2a) is a potent anticancer agent. Anticancer agent 44 shows cytotoxicity activity in cancer cells. Anticancer agent 44 induces apoptosis. Anticancer agent 44 shows low toxicity towards activated lymphocytes of human blood .
    Anticancer agent 44
  • HY-146290
    Anticancer agent 45

    		Apoptosis Cancer
    Anticancer agent 46 (compound 2b) is a potent and selective anticancer agent. Anticancer agent 46 shows cytotoxicity activity in cancer cells. Anticancer agent 46 induces apoptosis. Anticancer agent 46 shows low toxicity towards activated lymphocytes of human blood .
    Anticancer agent 45
  • HY-120635
    BMS-1001 hydrochloride

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM .
    BMS-1001 hydrochloride
  • HY-120647
    BMS-1001

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM .
    BMS-1001
  • HY-132297A
    PARP1-IN-5 dihydrochloride
    1 Publications Verification

    		 PARP Cancer
    PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .
    PARP1-IN-5 dihydrochloride
  • HY-132297
    PARP1-IN-5

    		PARP Cancer
    PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 can be used for the research of cancer .
    PARP1-IN-5
  • HY-13859
    Clevudine

    L-FMAU

    		 HBV DNA/RNA Synthesis Orthopoxvirus Infection
    Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .
    Clevudine
  • HY-120395
    UC-514321

    		STAT Apoptosis TET Protein Inflammation/Immunology Cancer
    UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity .
    UC-514321
  • HY-146683
    KS106

    		Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS106
  • HY-146682
    KS100

    		Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS100 is a potent ALDH inhibitor with IC50s of 230, 1542, 193 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS100 shows antiproliferative and anticancer effects with low low toxic. KS100 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS10600 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS100
  • HY-146595
    FtsZ-IN-1

    		Bacterial Infection
    FtsZ-IN-1 is a potent FtsZ inhibitor with quinolinium ring. FtsZ-IN-1 has stronger antibacterial activity against Gram-positive bacteria with MICs of 0.5-8 μg/mL. FtsZ-IN-1 significantly causes cell elongation of B. subtilis by enhancing FtsZ polymerization. FtsZ-IN-1 exhibits low hemolytic toxicity and low tendency to induce agent resistance. FtsZ-IN-1 has against drug-resistant bacteria activity .
    FtsZ-IN-1
  • HY-147841
    HIV-1 inhibitor-41

    		HIV Reverse Transcriptase Infection
    HIV-1 inhibitor-41 (Compound B23) is an orally active non-nucleoside HIV-1 reverse transcriptase inhibitor with EC50 values of 20.8 nM and 50 nM against HIV-1 WT and mutant E138K strain, respectively. HIV-1 inhibitor-41 shows low hERG, no apparent CYP enzymatic inhibition and no acute toxicity .
    HIV-1 inhibitor-41
  • HY-146384
    CRM1 degrader 1

    		CRM1 Cancer
    CRM1 degrader 1 (1l) is a low toxic chromosome region maintenance 1 (CRM1) degrader. CRM1 is the sole nuclear exporter of several tumor suppressor, a growth regulatory protein as an attractive cancer agent target. CRM1 degrader 1 induces the apoptosis in gastric carcinoma and selectively inhibits proliferation of gastric cancer .
    CRM1 degrader 1
  • HY-146354
    Antiproliferative agent-4

    		Apoptosis Reactive Oxygen Species Cancer
    Antiproliferative agent-4 (compound 2y) has excellent anti-proliferative activity against certain cancer cell lines. Antiproliferative agent-4 reduces the mitochondrial membrane potential, and increases the apoptosis rate and the level of ROS on EC109. Antiproliferative agent-4 inhibits tumour growth in nude mice, with low toxicity .
    Antiproliferative agent-4
  • HY-144653
    PDGFR-IN-1

    		PDGFR Apoptosis Cancer
    PDGFR-IN-1 (compound 7m) is a potent and orally active PDGFR (platelet-derived growth factor receptor) inhibitor, with IC50 values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma .
    PDGFR-IN-1
  • HY-145737
    PROTAC SOS1 degrader-1

    		PROTACs Ras Cancer
    PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .
    PROTAC SOS1 degrader-1
  • HY-19896
    COTI-2
    2 Publications Verification

    		 MDM-2/p53 Apoptosis Cancer
    COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .
    COTI-2
  • HY-145737A
    PROTAC SOS1 degrader-1 TFA

    		PROTACs Ras Cancer
    PROTAC SOS1 degrader-1 (TFA) is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .
    PROTAC SOS1 degrader-1 TFA
  • HY-135985
    DCLK1-IN-1
    1 Publications Verification

    		 Others Cancer
    DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1 + pancreatic ductal adenocarcinoma (PDAC) .
    DCLK1-IN-1
  • HY-144765
    NF-κB-IN-4

    		NF-κB Apoptosis Neurological Disease Inflammation/Immunology
    NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
    NF-κB-IN-4
  • HY-146691
    hMAO-B-IN-2

    		Monoamine Oxidase Neurological Disease
    hMAO-B-IN-2 (compound 6j) is an orally active, potent, selective and BBB penetrated and competitive reversible hMAO-B inhibitor, with an IC50 of 4 nM. hMAO-B-IN-2 shows low toxicity and good neuroprotective effects in SH-SY5Y cell. hMAO-B-IN-2 can be used for alzheimer’s disease research . hMAO-B-IN-2 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    hMAO-B-IN-2
  • HY-151436
    ZLMT-12

    		CDK Cholinesterase (ChE) Apoptosis Cancer
    ZLMT-12 (compound 35), tacrine derivatives, is a potent, orally active CDK2/9 inhibitor with IC50 values of 0.002 and 0.011 μM for CDK9 and CDK2, respectively. ZLMT-12 has a weak inhibitory effect on AChE (IC50=19.023 μM) and BChE (IC50=2.768 μM). ZLMT-12 has low toxicity and antiproliferative activity. ZLMT-12 induces apoptosis and arrests the cell cycle in the S phase and G2/M phase .
    ZLMT-12
  • HY-D1456
    TEPC466

    		Pyruvate Kinase Cancer
    TEPC466 is a novel TEPP-46-based aggregation-induced emission (AIE) probe. TEPC466 shows a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. EPC466 can be used for the detection of PKM2. TEPC466 is successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. TEPC466 is a useful tool for cancer diagnosis and research .
    TEPC466
  • HY-144056
    EGFR-IN-39

    		EGFR Cancer
    EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .
    EGFR-IN-39
  • HY-144055
    EGFR-IN-38

    		EGFR Cancer
    EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4) .
    EGFR-IN-38
  • HY-144054
    EGFR-IN-37

    		EGFR Cancer
    EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7) .
    EGFR-IN-37
  • HY-144052
    EGFR-IN-35

    		EGFR Cancer
    EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11) .
    EGFR-IN-35
  • HY-144051
    EGFR-IN-34

    		EGFR Cancer
    EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12) .
    EGFR-IN-34
  • HY-144050
    EGFR-IN-33

    		EGFR Cancer
    EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) .
    EGFR-IN-33
  • HY-100334
    Pirinixil

    BR-931

    		 Others Metabolic Disease
    Pirinixil is a hypolipidemic agent of low toxicity.
    Pirinixil
  • HY-B1073
    Morantel tartrate

    		Parasite Infection
    Morantel tartrate is a broad spectrum anthelmintic, effective and low toxicity.
    Morantel tartrate
  • HY-142287
    Con B-1

    		Anaplastic lymphoma kinase (ALK) Cancer
    ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .
    Con B-1
  • HY-B1217
    Bronopol

    BNPD; BNPK

    		 Bacterial Infection
    Bronopol is an antibacterial agent with low toxicity (to mammals) and high activity (especially against Gram-negative bacteria).
    Bronopol
  • HY-118165
    Phenthoate

    		Cholinesterase (ChE) Neurological Disease
    Phenthoate is an organophosphorus pesticide having low toxicity in animals. Phenthoate is also a AChE inhibitor .
    Phenthoate
  • HY-155067
    Antitubercular agent-38

    		Bacterial Infection
    Antitubercular agent-38 is an orally active Benzothiazinones (BTZs) derivate, with potent antituberculosis activity. Antitubercular agent-38 exhibits low cardiac toxicity, low cell cytotoxicity .
    Antitubercular agent-38
  • HY-123510
    NSC-670224

    		Others Others
    NSC-670224 is toxic to Saccharomyces cerevisiae at low micromolar concentration (LC50: 3.2 μM) .
    NSC-670224
  • HY-126428
    ZL0580

    		HIV Epigenetic Reader Domain Infection Inflammation/Immunology
    ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter .
    ZL0580
  • HY-116477
    URB937

    		FAAH Neurological Disease Inflammation/Immunology
    URB937 is an orally active and peripherally restricted FAAH inhibitor (IC50=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier) .
    URB937
  • HY-B0755
    Etimicin sulfate

    		Antibiotic Infection
    Etimicin (sulfate), a fourth-generation aminoglycoside antibiotic, is now widely clinically used due to its high efficacy and low toxicity.
    Etimicin sulfate
  • HY-151581
    HCVcc-IN-1

    		Virus Protease Infection
    HCVcc-IN-1 is a benzothiazole-2-thiophene S-glycoside derivative with low toxic and antiviral activity .
    HCVcc-IN-1
  • HY-13705
    NM-3

    		Others Cardiovascular Disease Inflammation/Immunology
    NM-3 is an isocoumarin with antiarthritic and antiangiogenic effects. NM-3 is an orally active antiangiogenic agent with low toxicity .
    NM-3
  • HY-B2010
    Fomesafen

    Fomesafen is a type of efficient and selective protoporphyrinogen IX oxidase (PPO) inhibitor. Fomesafen is a herbicide and has the advantages of low toxicity and high selectivity .
    Fomesafen

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: